Consolidation electrochemotherapy with bleomycin in metastatic melanoma during treatment with dabrafenib

Radiology and Oncology

Volumn 49, Issue 1, 2015, Pages 71-74

  Valpione, Sara ^a   Campana, Luca G ^a   Pigozzo, Jacopo ^a   Chiarion Sileni, Vanna ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

bleomycin; BRAF inhibitors; dabrafenib; electrochemotherapy; melanoma

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; BLEOMYCIN; CORTICOSTEROID; DABRAFENIB; IPILIMUMAB; TEMOZOLOMIDE;

AGED; ARTICLE; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CASE REPORT; CORTICOSTEROID THERAPY; DIARRHEA; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELECTROCHEMOTHERAPY; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERKERATOSIS; HYPOPHYSITIS; MALE; METASTATIC MELANOMA; PROGRAM EFFICACY; PRURITUS; QUALITY OF LIFE; RHINITIS; SOFT TISSUE METASTASIS; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR BIOPSY;

EID: 84929144224     PISSN: 13182099     EISSN: 15813207     Source Type: Journal    
DOI: 10.2478/raon-2014-0035     Document Type: Article

References (19)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000292199800006&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
2. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
3. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000310440800006&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
4. Mattei PL, Alora-Palli MB, Kraft S, Lawrence DP, Flaherty KT, Kimball AB. Cutaneous effects of BRAF inhibitor therapy: a case series. Ann Oncol 2013; 24: 530-7. 10.1093/annonc/mds292 23035153
5. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-6. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000316989900026&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
6. Rompoti N, Schilling B, Livingstone E, Griewank K, Hillen U, Sauerwein W, et al. Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity. J Clin Oncol 2013; 31: 3844-5. 10.1200/JCO.2013.50.8473
7. Ducassou A, David I, Delannes M, Chevreau C, Sibaud V. Radiosensitization induced by vemurafenib. Cancer Radiother 2013; 17: 304-7. 23810304 10.1016/j.canrad.2013.04.004 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000323994600007&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
8. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-40. 10.1016/j.ejso.2007.05.016 17614247
9. Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E, Sartore L, et al. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000303311600014&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1002/bjs.8749
10. Mir LG, L; Sersa, G; Collins, CG; Garbaya, GR; Billard, V; Geertsend, PF; et al. Standard operating procedures of the electrochemotherapy: Instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the CliniporatorTM by means of invasive or non-invasive electrodes. EJC Suppl 2006; 4: 14-25.
11. Belehradek M, Domenge C, Luboinski B, Orlowski S, Belehradek J, Jr., Mir LM. Electrochemotherapy, a new antitumor treatment. First clinical phase I-II trial. Cancer 1993; 72: 3694-700. 7504576 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2
12. Matthiessen LW, Chalmers RL, Sainsbury DC, Veeramani S, Kessell G, Humphreys AC, et al. Management of cutaneous metastases using electrochemotherapy. Acta Oncol 2011; 50: 621-9. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000290631600002&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.3109/0284186X.2011.573626
13. Campana LG, Testori A, Mozzillo N, Rossi CR. Treatment of metastatic melanoma with electrochemotherapy. J Surg Oncol 2014; 109: 301-7. 10.1002/jso.23512 24678530
14. Mali B, Jarm T, Snoj M, Sersa G, Miklavcic D. Antitumor effectiveness of electrochemotherapy: a systematic review and meta-analysis. Eur J Surg Oncol 2013; 39: 4-16. 22980492 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000315421700001&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1016/j.ejso.2012.08.016
15. Mali B, Miklavcic D, Campana LG, Cemazar M, Sersa G, Snoj M, et al. Tumor size and effectiveness of electrochemotherapy. Radiol Oncol 2013; 47: 32-41. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000317464100005&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3
16. Gerlini G, Sestini S, Di Gennaro P, Urso C, Pimpinelli N, Borgognoni L. Dendritic cells recruitment in melanoma metastasis treated by electrochemotherapy. Clin Exp Metastasis 2013; 30: 37-45. 22735940 http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000313709400004&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.1007/s10585-012-9505-1
17. Sersa G, Kotnik V, Cemazar M, Miklavcic D, Kotnik A. Electrochemotherapy with bleomycin in SA-1 tumor-bearing mice - natural resistance and immune responsiveness. Anticancer Drugs 1996; 7: 785-91. 10.1097/00001813-199609000-00011
18. Wilmott JS, Long GV, Howle JR, Haydu LE, Sharma RN, Thompson JF, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res 2012; 18: 1386-94. 10.1158/1078-0432.CCR-11-2479 22156613
19. Schilling B, Paschen A. Immunological consequences of selective BRAF inhibitors in malignant melanoma: Neutralization of myeloid-derived suppressor cells. Oncoimmunology 2013; 2: e25218. http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER-APP&SrcAuth=LinksAMR&KeyUT=WOS:000330424100020&DestLinkType=FullRecord&DestApp=ALL-WOS&UsrCustomerID=b7bc2757938ac7a7a821505f8243d9f3 10.4161/onci.25218